Senzar Asset Management Llc Lowered Position in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by $11.22 Million

May 17, 2018 - By Sheila Pollock

During Q4 2017 the big money sentiment decreased to 1.2. That’s change of 0.53, from 2017Q3’s 1.73. 23 investors sold all, 48 reduced holdings as AERI ratio dropped. 64 rose stakes while 21 funds bought stakes. Funds hold 34.86 million shares thus 1.29% more from 2017Q3’s 34.42 million shares. United Capital Advisers Ltd Com holds 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 5,515 shs. Dafna Cap Mgmt Limited Liability Corporation has 3.76% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Tradewinds Capital Management Llc accumulated 185 shs or 0.01% of the stock. Baker Bros Ltd Partnership has 299,356 shs. Bnp Paribas Arbitrage Sa owns 6,926 shs for 0% of their capital. 33,688 are owned by Partner Mgmt Limited Partnership. The United Kingdom-based Barclays Public Ltd Liability Corporation has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Fred Alger Mgmt holds 0.09% or 339,943 shs. Aperio Ltd Com, a California-based fund reported 5,721 shs. Iguana Health Mngmt Lc, a New York-based fund reported 85,000 shs. Neuberger Berman Grp Ltd Liability owns 261,500 shs or 0.02% of their US capital. Pictet Asset Mgmt Ltd reported 0.05% stake. Citadel Advisors Llc invested 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Ameriprise Finance stated it has 295,402 shs or 0.01% of all its holdings. 714 are held by Glenmede Company Na.

In Aerie Pharmaceuticals Inc (NASDAQ:AERI) was decreased the stake held by Senzar Asset Management Llc. The reduction is 74.62% according to 2018Q1 Securities and Exchange form. 207,732 shares were sold by Senzar Asset Management Llc as the company’s stock declined 12.77% with the market. The hedge fund is holding 70,668 shares, compared to the 278,400 from the previous quarter. And the reported value of the health care company is $3.83 million for the 2018Q1. $2.02 billion is Aerie Pharmaceuticals Inc’s market cap. AERI is hitting $51.2 during the last trading session, after increased 1.59%.Aerie Pharmaceuticals, Inc. has volume of 224,990 shares. Since May 17, 2017 AERI has risen 16.25% and is uptrending. The stock outperformed the S&P 500 by 4.70%.

Senzar Asset Management Llc has risen its stake in and also increased its holding in by shares in the quarter, for a total of shares.

Senzar Asset Management Llc is a New York-based hedge fund with more than $442.00 million AUM in December, 2014. Taken from Senzar Asset Management latest Adv, the fund reported to have 7 full and part-time employees. Among which 4 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

In total 6 analysts cover Aerie Pharma (NASDAQ:AERI). “Buy” rating has 6, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 11 are the (NASDAQ:AERI)’s analyst reports since December 18, 2017 according to StockzIntelligence Inc. On Wednesday, May 9 the firm has “Buy” rating given by Mizuho. The company rating was maintained by Canaccord Genuity on Wednesday, January 24. On Thursday, March 1 the rating was maintained by H.C. Wainwright with “Buy”. On Wednesday, May 9 H.C. Wainwright maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) with “Buy” rating. On Monday, December 18 Cantor Fitzgerald maintained the shares of AERI in report with “Buy” rating. On Tuesday, January 2 Stifel Nicolaus maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating. Stifel Nicolaus has “Buy” rating and $80.0 target. On Thursday, March 29 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Mizuho. On Friday, February 16 the rating was reinitiated by H.C. Wainwright with “Buy”. On Wednesday, February 28 Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating. Cantor Fitzgerald has “Buy” rating and $86.0 target. On Tuesday, May 8 the rating was maintained by Cantor Fitzgerald with “Buy”.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The company has $2.02 billion market cap. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Last it reported negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: